FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4211183522> ?p ?o ?g. }

• W4211183522 abstract "Background The treatment of choice for moderate to severe obstructive sleep apnoea (OSA) is continuous positive airways pressure (CPAP) via a mask during sleep. However this is not tolerated by all patients and its role in mild OSA is not proven. Drug therapy has been proposed as an alternative to CPAP in some patients with mild to moderate sleep apnoea and could be of value in patients intolerant of CPAP. A number of mechanisms have been proposed by which drugs could reduce the severity of OSA. These include an increase in tone in the upper airway dilator muscles, an increase in ventilatory drive, a reduction in the proportion of REM sleep, an increase in cholinergic tone during sleep, a reduction in airway resistance and a reduction in surface tension in the upper airway. Objectives To determine the efficacy of drug therapies in the treatment of sleep apnoea. Search methods We carried out searches on the Cochrane Airways Group Specialised Register of trials. Searches were current as of July 2006. Selection criteria Randomised, placebo controlled trials involving adult patients with confirmed OSA . We excluded trials if continuous positive airways pressure, mandibular devices or oxygen therapy were used. No restriction was placed upon publication language or trial duration. Data collection and analysis Two reviewers independently assessed studies for inclusion, undertook data extraction according to pre‐specified entry criteria, and quality assessment of studies. No response for further information was forthcoming from study authors. Results were expressed as mean differences and 95% Confidence Intervals (CI). Main results Twenty‐six trials of 21 drugs, involving 394 participants contributed data to the review. Most of the studies were small and many trials had methodological limitations. Each of the studies states that the subjects had OSA but diagnostic criteria were not always explicit and it is possible that some patients with central apnoeas may have been recruited. Six drugs had some impact on OSA severity and two altered daytime symptoms. One study reported that apnoea hypopnea index (AHI) was lower following treatment with intranasal fluticasone compared with placebo (23.3 versus 30.3) in 24 participants with sleep apnoea and rhinitis. Subjective alertness in the daytime also improved. Physostigmine gave an AHI of 41 compared to 54 on placebo (10 participants) and in a similar study Mirtazipine 15 mg produced an AHI of 13 compared to 23.7 for placebo (10 participants). Topical nasal lubricant given twice overnight resulted in an AHI of 14 compared to 24 with placebo (10 participants). These three latter studies were of single night crossover design and so there are no data on the acceptability of these treatments or their effect on symptoms. Paroxetine was shown to reduce AHI to 23.3 compared to 30.3 for placebo, most of the 20 participants tolerated the treatment but there was no improvement in daytime symptoms. Acetazolamide also reduced the AHI (one crossover trial of nine patients, mean difference 24 (95% CI 4 to 44). However there was no symptomatic benefit from the drug and it was poorly tolerated in the long term. Protriptyline led to a symptomatic improvement (improved versus not improved) in two out of three crossover trials (13 participants, Peto Odds Ratio 29.2 (95% CI 2.8 to 301.1) but there was no change in the apnoea frequency. In one trial naltrexone did reduce AHI, but total sleep time favoured placebo. No significant beneficial effects were found for medroxy progesterone, clonidine, mibefradil, cilazapril, buspirone, aminophylline, theophylline doxapram, ondansetron or sabeluzole. Authors' conclusions There is insufficient evidence to recommend the use of drug therapy in the treatment of OSA. Small studies have reported positive effects of certain agents on short‐term outcome. Certain agents have been shown to reduce the AHI in largely unselected populations with OSA by between 24 and 45%. For fluticasone, mirtazipine, physostigmine and nasal lubricant, studies of longer duration are required to establish whether this has an impact on daytime symptoms. Individual patients had more complete responses to particular drugs. It is likely that better matching of drugs to patients according to the dominant mechanism of their OSA will lead to better results and this also needs further study." @default.
• W4211183522 created "2022-02-13" @default.
• W4211183522 creator A5035383163 @default.
• W4211183522 creator A5064914332 @default.
• W4211183522 creator A5083748988 @default.
• W4211183522 date "2006-04-19" @default.
• W4211183522 modified "2023-10-18" @default.
• W4211183522 title "Drug therapy for obstructive sleep apnoea in adults" @default.
• W4211183522 cites W15934280 @default.
• W4211183522 cites W1602374362 @default.
• W4211183522 cites W1740551982 @default.
• W4211183522 cites W1832638211 @default.
• W4211183522 cites W1837929068 @default.
• W4211183522 cites W1940217509 @default.
• W4211183522 cites W1954995557 @default.
• W4211183522 cites W1969688274 @default.
• W4211183522 cites W1971519521 @default.
• W4211183522 cites W1977996151 @default.
• W4211183522 cites W1978410284 @default.
• W4211183522 cites W1980649853 @default.
• W4211183522 cites W1981417640 @default.
• W4211183522 cites W1982256190 @default.
• W4211183522 cites W1982431300 @default.
• W4211183522 cites W1985551641 @default.
• W4211183522 cites W1986188869 @default.
• W4211183522 cites W1986215651 @default.
• W4211183522 cites W1987389183 @default.
• W4211183522 cites W1991604571 @default.
• W4211183522 cites W1994156730 @default.
• W4211183522 cites W1994379541 @default.
• W4211183522 cites W1998056046 @default.
• W4211183522 cites W2010133027 @default.
• W4211183522 cites W2012491333 @default.
• W4211183522 cites W2013091540 @default.
• W4211183522 cites W2014884602 @default.
• W4211183522 cites W2025104836 @default.
• W4211183522 cites W2029274857 @default.
• W4211183522 cites W2031501096 @default.
• W4211183522 cites W2034137604 @default.
• W4211183522 cites W2037136588 @default.
• W4211183522 cites W2037737187 @default.
• W4211183522 cites W2038364855 @default.
• W4211183522 cites W2045089773 @default.
• W4211183522 cites W2048468809 @default.
• W4211183522 cites W2051122156 @default.
• W4211183522 cites W2054995170 @default.
• W4211183522 cites W2055431030 @default.
• W4211183522 cites W2063601988 @default.
• W4211183522 cites W2070866648 @default.
• W4211183522 cites W2071173597 @default.
• W4211183522 cites W2075726900 @default.
• W4211183522 cites W2077041314 @default.
• W4211183522 cites W2081857091 @default.
• W4211183522 cites W2082533403 @default.
• W4211183522 cites W2085814883 @default.
• W4211183522 cites W2093737681 @default.
• W4211183522 cites W2093953787 @default.
• W4211183522 cites W2097102461 @default.
• W4211183522 cites W2100366158 @default.
• W4211183522 cites W2123641217 @default.
• W4211183522 cites W2124586699 @default.
• W4211183522 cites W2125435699 @default.
• W4211183522 cites W2128103058 @default.
• W4211183522 cites W2132610832 @default.
• W4211183522 cites W2135819242 @default.
• W4211183522 cites W2146028771 @default.
• W4211183522 cites W2149626929 @default.
• W4211183522 cites W2159891325 @default.
• W4211183522 cites W2161061887 @default.
• W4211183522 cites W2164803013 @default.
• W4211183522 cites W2333049064 @default.
• W4211183522 cites W2395807974 @default.
• W4211183522 cites W2410910973 @default.
• W4211183522 cites W2416432703 @default.
• W4211183522 cites W2442098558 @default.
• W4211183522 cites W4243215475 @default.
• W4211183522 cites W4245325947 @default.
• W4211183522 cites W4367031099 @default.
• W4211183522 cites W65017333 @default.
• W4211183522 doi "https://doi.org/10.1002/14651858.cd003002.pub2" @default.
• W4211183522 hasPublicationYear "2006" @default.
• W4211183522 type Work @default.
• W4211183522 citedByCount "38" @default.
• W4211183522 countsByYear W42111835222012 @default.
• W4211183522 countsByYear W42111835222013 @default.
• W4211183522 countsByYear W42111835222014 @default.
• W4211183522 countsByYear W42111835222015 @default.
• W4211183522 countsByYear W42111835222016 @default.
• W4211183522 countsByYear W42111835222017 @default.
• W4211183522 countsByYear W42111835222018 @default.
• W4211183522 countsByYear W42111835222019 @default.
• W4211183522 countsByYear W42111835222022 @default.
• W4211183522 crossrefType "reference-entry" @default.
• W4211183522 hasAuthorship W4211183522A5035383163 @default.
• W4211183522 hasAuthorship W4211183522A5064914332 @default.
• W4211183522 hasAuthorship W4211183522A5083748988 @default.
• W4211183522 hasConcept C105922876 @default.
• W4211183522 hasConcept C111919701 @default.
• W4211183522 hasConcept C126322002 @default.
• W4211183522 hasConcept C142724271 @default.

• next